GlycoMimetics to Participate in Upcoming Jefferies 2023 Healthcare Con...

Your unfiltered news center. ®

The world you see depends upon the news you get. ®

HOME

ARTS

RSS

Today's Date: October 4, 2023

CAMS Wins Ragan CSR, ESG and Diversity Awards • NAREB's 60-CITY, BLACK WEALTH TOUR BEGINS IN HOUSTON WITH A COMMUNITY WEALTH BUILDING DAY • Vancouver International Airport Selects LAT Multilingual to Engage with Chinese Travellers • Get a Free Google Pixel 8 and Unleash its Full 5G Potential Only at T-Mobile, America’s 5G Leader • Illume Fertility Founder and Medical Director, Dr. Mark Leondires, Co-Authors the First All-Inclusive Guide to Donor Conception • Investments and Innovations Drive Expansion of Europe's Elderly Care Medical Devices Market • ACE Cash Express Supports Homes For Our Troops to Help Veterans Rebuild Their Lives • Grupo EULEN announces Angeles Campoy as the New Chief Executive Officer for USA • Consumers Energy Continues Clean Energy Transition with Plans for Solar Project at Former Coal Plant Location • Global Clean Energy Reports Largest Camelina Acreage Worldwide • FINRA Foundation Awards 2023 Ketchum Prize to Long-Time Financial Fraud Fighter Doug Shadel • MERGE Acquires Zee Jay Digital to Orchestrate the Content Supply Chain for Superior CX • KIA AMERICA HONORS SEASON 18 WINNER OF "AMERICA'S GOT TALENT" • Avangrid Schedules Third Quarter 2023 Earnings Release and Conference Call • Statement - Ministers Anandasangaree, Vandal, Hajdu, and Ien issue a statement of support on Sisters in Spirit Day and the Natio • How Student Retention Teams Are Saving High School Dropouts • Indie Beauty and Wellness Brand LĀ SOL Collective Expands Product Line with HYDRATE Body Oil • Six wheelchair tennis players nominated to Santiago 2023 Canadian Parapan Am Team • Patrick and Brittany Mahomes’ 15 and the Mahomies Foundation Establishes National Partnership With Boys & Girls Clubs • Qwoted Launches Free Networking Tools for PR Industry

GlycoMimetics to Participate in Upcoming Jefferies 2023 Healthcare Conference

ROCKVILLE, Md. , May 31 /Businesswire/ - GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that Harout Semerjian, Chief Executive Officer, will participate in a fireside chat at the Jefferies Healthcare Conference in New York, NY on Wednesday, June 7, 2023 at 4:00 p.m. ET.

A live webcast of the fireside chat will be available on the GlycoMimetics website at https://ir.glycomimetics.com/investor-relations. An archived recording will be available for 30 days following the event.

About GlycoMimetics, Inc.

GlycoMimetics is a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers, including AML, and for inflammatory diseases with high unmet needs. The company’s science is based on an understanding of the role that carbohydrates play in cell recognition and its specialized chemistry platform to discover small molecule drugs, known as glycomimetics, which alter carbohydrate-mediated recognition in diverse disease states, including cancer and inflammation. As a leader in this science, GlycoMimetics leverages this unique approach to advance its pipeline of wholly-owned drug candidates, with the goal of developing transformative therapies for diseases with high unmet need. GlycoMimetics is headquartered in Rockville, MD in the BioHealth Capital Region. Learn more at www.glycomimetics.com.

Forward-Looking Statements

This press release contains forward-looking statements. These forward-looking statements may include, but are not limited to, statements regarding the conduct of and data from clinical trials, planned or potential clinical development, regulatory interactions and submissions, the commercialization and potential benefits and impact of the Company’s drug candidates, and the Company’s expected cash runway. Actual results may differ materially from those described in these forward-looking statements. For a further description of the risks associated with these statements, as well as other risks facing GlycoMimetics, please see the risk factors described in the Company’s Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on March 3, 2022, its Quarterly Report on Form 10-Q filed with the SEC on November 9, 2022, and other filings GlycoMimetics makes with the SEC from time to time. Forward-looking statements speak only as of the date of this release, and GlycoMimetics undertakes no obligation to update or revise these statements, except as may be required by law.